Close
Company Search
Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Glaxosmithkline (GSK) Share Price

Price 1,862.00p on 29-04-2026 at 14:32:27
Change -166.00p -8.19%
Buy 1,862.50p
Sell 1,861.50p
Add to Watchlist
Add to Portfolio
Add to Quickpicks
Last Trade: Buy 148.00 at 1,862.00p
Day's Volume: 9,272,631
Last Close: 2,028.00p
Open: 2,050.00p
ISIN: GB00BN7SWP63
Day's Range 1,850.50p - 2,051.00p
52wk Range: 1,315.00p - 2,282.00p
Market Capitalisation: £74.33b
VWAP: 1,947.34391p
Shares in Issue: 3.99b

Sector: Medicine and Biotech

Listed In: FTSE All-Share, FTSE All-Share ex Investment Trusts, FTSE Higher Yield, FTSE 350 ex Investment Trusts, FTSE 350 , FTSE 100,

Glaxosmithkline (GSK) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Buy* 148 1,862.00p Automatic Execution
 15:32:17 - 29-Apr-26
Buy* 88 1,862.00p Automatic Execution
 15:32:17 - 29-Apr-26
Buy* 475 1,862.00p Automatic Execution
 15:32:17 - 29-Apr-26
Buy* 257 1,862.00p Automatic Execution
 15:32:17 - 29-Apr-26
Buy* 324 1,862.00p Automatic Execution
 15:32:17 - 29-Apr-26
Buy* 5 1,862.00p SI Trade
 15:32:16 - 29-Apr-26
Buy* 462 1,861.50p Automatic Execution
 15:32:12 - 29-Apr-26
Buy* 3,000 1,861.50p Automatic Execution
 15:32:12 - 29-Apr-26
Buy* 736 1,861.50p Automatic Execution
 15:32:12 - 29-Apr-26
Buy* 736 1,861.00p Automatic Execution
 15:32:10 - 29-Apr-26
See more Glaxosmithkline trades

Glaxosmithkline (GSK) Share Price History

Time period:
to
Date Open High Low Close Volume
28th Apr 2026 (Tue) 1,964.50 2,038.00 1,964.50 2,028.00 10,393,498
27th Apr 2026 (Mon) 2,018.00 2,023.00 1,999.50 2,016.00 10,818,753
24th Apr 2026 (Fri) 2,070.00 2,071.00 2,020.00 2,020.00 4,689,325
23rd Apr 2026 (Thu) 2,055.00 2,083.00 2,053.00 2,076.00 9,031,937
22nd Apr 2026 (Wed) 2,082.00 2,093.00 2,073.00 2,075.00 6,988,214
21st Apr 2026 (Tue) 2,124.00 2,130.00 2,071.00 2,082.00 5,986,607
20th Apr 2026 (Mon) 2,145.00 2,156.00 2,134.00 2,144.00 4,715,270
17th Apr 2026 (Fri) 2,122.00 2,144.00 2,115.00 2,144.00 5,135,113
16th Apr 2026 (Thu) 2,121.00 2,135.00 2,115.00 2,123.00 4,358,573
15th Apr 2026 (Wed) 2,198.00 2,202.00 2,131.00 2,131.00 6,008,590
14th Apr 2026 (Tue) 2,170.00 2,195.00 2,164.00 2,190.00 4,785,341
13th Apr 2026 (Mon) 2,151.00 2,180.00 2,151.00 2,170.00 6,947,099
10th Apr 2026 (Fri) 2,156.00 2,196.00 2,156.00 2,176.00 8,127,125
9th Apr 2026 (Thu) 2,141.00 2,167.00 2,124.00 2,167.00 6,632,002
8th Apr 2026 (Wed) 2,126.00 2,142.00 2,104.00 2,125.00 9,481,975
7th Apr 2026 (Tue) 2,129.00 2,137.00 2,083.00 2,096.00 5,857,080
6th Apr 2026 (Mon) 2,144.00 2,144.00 2,144.00 2,144.00 0
3rd Apr 2026 (Fri) 2,144.00 2,144.00 2,144.00 2,144.00 0
2nd Apr 2026 (Thu) 2,097.00 2,161.00 2,090.00 2,144.00 6,448,889
1st Apr 2026 (Wed) 2,072.00 2,122.00 2,072.00 2,107.00 6,204,094
31st Mar 2026 (Tue) 2,064.00 2,086.00 2,064.00 2,064.00 15,704,368
30th Mar 2026 (Mon) 2,051.00 2,070.00 2,044.00 2,063.00 9,872,668
See more Glaxosmithkline price history

Glaxosmithkline (GSK) Regulatory News

Date Source Headline
28th Apr 2026 3:30 pm RNS Director/PDMR Shareholding
28th Apr 2026 7:00 am RNS Bepirovirsen priority review US filing acceptance
27th Apr 2026 12:00 pm RNS Efimosfermin granted US/EU regulatory designations
27th Apr 2026 7:00 am RNS TESARO update on AnaptysBio Inc. litigation
24th Apr 2026 3:30 pm RNS Director/PDMR Shareholding
23rd Apr 2026 7:00 am RNS Transaction in Own Shares
22nd Apr 2026 7:00 am RNS Transaction in Own Shares
21st Apr 2026 7:00 am RNS Transaction in Own Shares
20th Apr 2026 3:30 pm RNS Director/PDMR Shareholding
20th Apr 2026 7:00 am RNS Blenrep approved in China for 2L+ multiple myeloma
See more Glaxosmithkline regulatory news

Glaxosmithkline (GSK) Share News

UK shareholder meetings calendar - next 7 days

29th Apr 2026 14:55

Read More

LONDON BRIEFING: AstraZeneca, Lloyds, GSK post first-quarter growth

29th Apr 2026 07:59

(Alliance News) - AstraZeneca, Lloyds Banking Group and GSK report higher earnings in the first quarter. Read More

IN BRIEF: GSK given fast-track review by US FDA for hepatitis B drug

28th Apr 2026 09:25

GSK PLC - London-based pharmaceuticals maker - Bepirovirsen, GSK's treatment for chronic hepatitis B, is accepted for priority review and given 'breakthrough therapy designation' by the US Food & Drug Administration. GSK says the fast track approval process for its new drug application recognises bepirovirsen's potential for substantial improvement over existing treatments. Chronic hepatitis is a leading cause of liver cancer, and bepirovirsen, an investigational antisense oligonucleotide, showed "clinically meaningful functional cure rates" in phase III trials of adults. The FDA sets October 26 as its goal date for a decision on the drug application. Read More

GSK's liver treatment efimosfermin makes US, EU regulatory progress

27th Apr 2026 12:51

(Alliance News) - GSK PLC on Monday announced two positive regulatory rulings for efimosfermin, a once-monthly investigational liver therapy. Read More

US court dismisses part of GSK subsidiary's licence dispute claim

27th Apr 2026 08:33

(Alliance News) - GSK PLC on Monday said a US court has dismissed part of a legal claim involving its subsidiary Tesaro Inc. Read More

See more Glaxosmithkline news
FTSE 100 Latest
Value10,206.24
Change-126.55

Login to your account

Forgot Password?

Not Registered